Pink Crystal 98% Purity Substituted Methylenedioxyphenethylamine

hylenedioxy analog of methcathinone. The only structural difference of methylone with respect to MDMA is the substitution of 2 hydrogen atoms by 1 oxygen atom in the β position of the phenethylamine core, forming a ketone group.

Methylone was first synthesized by the chemists Peyton Jacob III and Alexander Shulgin in 1996 for potential use as an antidepressant.

 Starting around 2004, methylone has been sold for recreational use, taking advantage of the absence of legal prohibition of this compound in many countries.

3. Pharmacology 

Ethylone acts as a mixed reuptake inhibitor/releasing agent of serotonin, norepinephrine, and dopamine.These are the neurotransmitters in charge of pleasure, reward, motivation and focus.
This is done by inhibiting the reuptake and reabsorption of the neurotransmitters after they have performed their function of transmitting a neural impulse, essentially allowing them to accumulate and be reused, causing physically stimulating and euphoric effects.
 
In comparison to methylone, it has approximately over 3x lower affinity for the serotonin transporter (which itself has 3x lower affinity than MDMA), while its affinity for the norepinephrine and dopamine transporters is similar.
 
 The results of these differences in pharmacology relative to methylone is that ethylone is less potent in terms of dose, has more balanced catecholaminergic effects relative to serotonergic, and behaves more like a reuptake inhibitor like methylphenidate than a releaser like amphetamine; however, ethylone still has relatively robust releasing capabilities.